Gross Profit Trends Compared: Amgen Inc. vs Halozyme Therapeutics, Inc.

Biotech Giants: Amgen vs. Halozyme Profit Trends

__timestamp	Amgen Inc.	Halozyme Therapeutics, Inc.
Wednesday, January 1, 2014	15641000000	52602000
Thursday, January 1, 2015	17435000000	105812000
Friday, January 1, 2016	18829000000	113485000
Sunday, January 1, 2017	18780000000	285461000
Monday, January 1, 2018	19646000000	141726000
Tuesday, January 1, 2019	19006000000	150446000
Wednesday, January 1, 2020	19265000000	224227000
Friday, January 1, 2021	19525000000	361897000
Saturday, January 1, 2022	19917000000	520812000
Sunday, January 1, 2023	19775000000	636892000

Infusing magic into the data realm

A Tale of Two Biotech Giants: Amgen Inc. vs. Halozyme Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, Amgen Inc. and Halozyme Therapeutics, Inc. have carved distinct paths. From 2014 to 2023, Amgen's gross profit consistently dwarfed that of Halozyme, showcasing its dominance in the sector. Amgen's gross profit surged by approximately 26% over this period, peaking in 2022. In contrast, Halozyme, while smaller, demonstrated impressive growth, with its gross profit increasing by over 1,100%, reflecting its dynamic expansion strategy.

This comparison highlights the diverse strategies within the biotech industry. Amgen's steady growth underscores its established market presence, while Halozyme's rapid rise points to its innovative approaches. As the biotech sector continues to grow, these trends offer valuable insights into the strategies that drive success.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025